MACO-355 / Macomics - LARVOL DELTA

MACO-355, a unique pan-LILR monoclonal antibody for cancer therapy, re-programs and stimulates immuno-suppressive macrophages in a novel ligand-binding blocking independent manner. (AACR 2024) - "This appears to occur via a novel mode of action in which MACO-355 clusters multiple LILRs with Fc-receptors into unconventional signaling hubs. Altogether the data support the future clinical evaluation of MACO-355 as a cancer therapeutic."

Late-breaking abstract • Melanoma • Oncology • Solid Tumor • CSF1 • HLA-E • IL10 • IL4 • LILRB1 • LILRB2 • TGFB1

Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024 (GlobeNewswire) - "Tested head-to-head against reference antibodies, MACO-355 was the only antibody able to activate highly immune-suppressed macrophages. Data presented also showed that it reverts M2 (TGFβ/IL-10/IL-4) macrophage mediated suppression of T cell activity in vitro and slows tumour growth in vivo...MACO-355 binds to selected members of LILRB and targets a unique, membrane proximal epitope. It requires engagement of Fc receptor(s) for full activity and rewires the macrophage kinase network in a novel mode of action. Macomics hypothesizes that by having activity independent of the ligand status of the tumour, and the ability to activate highly immunosuppressed macrophages will translate into increased efficacy in clinic and provide opportunity for biomarker-led patient stratification."

Preclinical • Oncology

Discovery of MACO-355, a novel, first in mechanism ligand-blocking independent anti-LILRB1/2 monoclonal antibody for cancer therapy (SITC 2023) - "Conclusions MACO-355 is a first in mechanism ligand-blocking independent LILRB1/2 antibody and is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions. These data support the future clinical evaluation of MACO-355 as a cancer therapeutic."

Oncology • Solid Tumor • HLA-E • IFNG • IL10 • LILRB1 • LILRB2